Company Overview
Pelthos Therapeutics Inc. operates as a bio-pharmaceutical entity dedicated to developing and commercializing therapeutic products designed to address significant unmet treatment burdens for patients. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it focuses on creating innovative solutions for conditions that lack adequate existing therapies. Its operational scale is defined by a market capitalization of $75.47M, an annual revenue of $16.80M, and a workforce consisting of 92 employees. These financial figures indicate that Pelthos Therapeutics Inc. is a mid-cap biotechnology firm with a relatively small employee base, suggesting a lean operational structure typical of companies in the early-to-mid stages of product commercialization that rely heavily on R&D investment and strategic partnerships to achieve market penetration.
Financial Health
The company reported a revenue of $16.80M over the trailing twelve months, yet this revenue generated a net income of $-43,319,000, revealing a cost structure where expenses significantly outpace income generation. This substantial gap between revenue and net income highlights the heavy burn rate often associated with biotechnology firms developing complex therapeutic assets like ZELSUVMI and ozenoxacin cream. The company's free cash flow stands at $-24,652,500, which indicates a lack of positive cash generation from operations and implies limited financial flexibility without external capital raises or asset monetization. Margin analysis shows a gross margin of 68.9%, suggesting favorable pricing or low direct manufacturing costs relative to sales, while the operating margin of -127.8% and profit margin of -257.9% demonstrate that general and administrative expenses, along with research and development costs, are aggressively diluting profitability. The balance sheet presents a leveraged position with total debt of $34.83M against cash holdings of $17.97M, resulting in a debt-to-equity ratio of 89.58%. Despite this leverage, the current ratio of 2.06 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities more than twice over. Return on equity is reported at -239.6% and return on assets at -29.8%, metrics that reflect how management is deploying capital; in this context, the negative returns are consistent with a growth-stage biotech company investing heavily in future products rather than generating immediate shareholder value.
Valuation Assessment
Valuation metrics for Pelthos Therapeutics Inc. show a trailing P/E ratio of N/A and a forward P/E of -51.90, a disparity that implies earnings are currently negative and future earnings trajectories remain unproven until profitability is achieved. The price-to-book ratio is 1.87, indicating that the market values the company at a premium of 87% over its net asset book value, likely reflecting intangible assets such as intellectual property and pipeline potential rather than tangible infrastructure. Alternative valuation metrics include a price-to-sales ratio of 4.49 and an EV/EBITDA of -3.17, which suggest the market is pricing the company based on sales multiples rather than earnings power, a common practice for pre-profitable biotechnology firms. Price action data reveals a 52-week high of $54.29 and a 52-week low of $9.00, meaning the stock has experienced extreme volatility ranging from a high of approximately 602% above the low to a significant correction from the highs. The stock exhibits a beta of 3.94, which signifies that the share price is highly volatile and tends to fluctuate roughly four times as much as the broader market, exposing investors to substantial price swings during periods of market uncertainty.
Growth & Income
Regarding growth metrics, the revenue growth year-over-year is listed as N/A and earnings growth year-over-year is also N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific reporting period. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company reinvests all available earnings and capital into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies that must fund ongoing clinical trials and regulatory approvals to bring new therapies to market before they can sustainably fund dividends. Consequently, the overall growth and income profile for Pelthos Therapeutics Inc. is characterized by a lack of current income generation and reliance on capital markets for funding, with growth prospects entirely dependent on the successful commercialization of its therapeutic portfolio including ZELSUVMI and XEPI.